Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer

NCT01391143 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT01391143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01391143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2011
Completion date
April 18, 2019
Enrollment
179 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, head and neck cancer, melanoma, non-small cell lung cancer, prostate cancer, renal cell carcinoma, triple-negative breast cancer